

# MxB Polyclonal Antibody

Catalog # AP71108

## Product Information

---

<b>Application</b>	WB
<b>Primary Accession</b>	<a href="#">P20592</a>
<b>Reactivity</b>	Human
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	82089

## Additional Information

---

<b>Gene ID</b>	4600
<b>Other Names</b>	MX2; Interferon-induced GTP-binding protein Mx2; Interferon-regulated resistance GTP-binding protein MxB; Myxovirus resistance protein 2; p78-related protein
<b>Dilution</b>	WB~~Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications.
<b>Format</b>	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.
<b>Storage Conditions</b>	-20°C

## Protein Information

---

<b>Name</b>	MX2
<b>Function</b>	Interferon-induced dynamin-like GTPase with potent antiviral activity against human immunodeficiency virus type 1 (HIV-1). Acts by targeting the viral capsid and affects the nuclear uptake and/or stability of the HIV-1 replication complex and the subsequent chromosomal integration of the proviral DNA. Exhibits antiviral activity also against simian immunodeficiency virus (SIV-mnd). May play a role in regulating nucleocytoplasmic transport and cell-cycle progression.
<b>Cellular Location</b>	Cytoplasm. Nucleus. Nucleus, nuclear pore complex. Note=Localization to nuclear pores requires GTP-binding

## Background


---

Interferon-induced dynamin-like GTPase with potent antiviral activity against human immunodeficiency virus type 1 (HIV-1). Acts by targeting the viral capsid and affects the nuclear uptake and/or stability of the

HIV-1 replication complex and the subsequent chromosomal integration of the proviral DNA. Exhibits antiviral activity also against simian immunodeficiency virus (SIV-mnd). May play a role in regulating nucleocytoplasmic transport and cell-cycle progression.

## Images

---



Western Blot analysis of 293 cells using MxB Polyclonal Antibody

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.